i-factor - search results

If you're not happy with the results, please do another search

ISASS bone grafting policy statement features i-FACTOR peptide enhanced bone graft

The International Society for the Advancement of Spine Surgery (ISASS) recently issued a new bone grafting policy that features i‑FACTOR peptide enhanced bone graft...

IVANOS study reveals i-FACTOR bone graft use more than doubles fusion rate when compared...

Level 1 evidence, presented at EUROSPINE 2018 in Barcelona, Spain, demonstrates that i-FACTOR peptide enhanced bone graft results in significantly higher rates of fusion...
financing

Use of i-FACTOR peptide enhanced bone graft more than doubles fusion rate in uninstrumented...

The use of i-FACTOR peptide enhanced bone graft (Cerapedics) resulted in a 50% fusion rate, compared to a 20% fusion rate using allograft in...
i-FACTOR bone graft Cerapedics

i-FACTOR™: Small peptide, big impact

This article is sponsored by Cerapedics, Inc. A FAST, RELIABLE AND PROVEN ALTERNATIVE TO AUTOGRAFT i-FACTOR peptide-enhanced bone graft is challenging the gold standard in bone...

Two-year results show statistical superiority of Cerapedics’ I-Factor to autograft in cervical spine

Cerapedics has announced the publication of two-year follow-up data from a US Food and Drug Administration (FDA) Investigational Device Exemption (IDE) clinical trial of...

Cerapedics awarded group purchasing agreement with Premier for I-Factor

Cerapedics has been awarded a group purchasing agreement with Premier, a healthcare improvement company. The new agreement allows Premier members, at their discretion, to take...

FDA advisory committee panel not required for i-FACTOR premarket approval

An advisory committee panel meeting will not be required for the final review of the premarket approval application for i-FACTOR peptide enhanced bone graft.

Study supports use of i-FACTOR as alternative to autograft in chronic back pain surgery

i-FACTOR biologic bone graft features synthetic small peptide (P-15) technology that supports bone growth through cell attachment and osteoblast differentiation.

Cerapedics receives CE mark and TGA listing for i-FACTOR Flex FR biologic bone graft

P-15 bone graft technology now features enhanced handling with addition of purified silk fibres.

Cerapedics files PMA application with FDA for i-FACTOR peptide enhanced bone graft

The PMA application is supported by data from a pivotal clinical trial demonstrating that i-FACTOR bone graft can be used as an alternative to autograft harvesting in certain procedures.
cerapedics

Cerapedics announces expansion of Colorado headquarters

Cerapedics has announced the expansion of the company's headquarters located in the Denver metropolitan area. Over the past 18 months, Cerapedics has grown from...
IDE

Cerapedics announces first patients enrolled in IDE clinical trial of P-15L bone graft for...

  The first patients have been enrolled in an investigational device exemption (IDE) clinical trial evaluating the safety and efficacy of the next-generation P-15L peptide...
financing

Cerapedics announces closing of US$22 million financing

Cerapedics has announced that the company completed a US$22 million financing led by KCK Group, a family investment fund that focuses on innovative medical...

Cerapedics receives FDA approval to initiate IDE study of P-15L bone graft for TLIF...

Cerapedics, a privately-held orthobiologics company, has announced the company received approval from the US Food and Drug Administration (FDA) to initiate an investigational device...
I-factor peptide-enhanced bone graft

Peptide-enhanced bone graft outperforms autograft at two years

A prospective, multicentre trial has found that a peptide-enhanced bone graft is non-inferior compared to local autograft bone. In addition, the bone graft outperformed...

Novel biologic bone graft improves clinical outcomes in ALIF procedures

A new study published in the Journal of Neurosurgery: Spine indicates that Cerapedics' i-Factor biologic bone graft improves clinical outcomes patients undergoing ALIF.

Tim Pigott

Ronald Bartels

Matthew Scott-Young